Literature DB >> 9951496

Scoring systems for measuring progression of visual field loss in clinical trials of glaucoma treatment.

J Katz1.   

Abstract

OBJECTIVES: To compare the statistical properties of two visual field scoring systems used by clinical trials of glaucoma treatments with a view to their performance as longitudinal measures of visual field progression.
DESIGN: Cohort study comparing the scoring systems used by the Advanced Glaucoma Intervention Study (AGIS) and the Collaborative Initial Glaucoma Treatment Study (CIGTS) using pairs of visual fields (C-30-2 of the Humphrey Analyzer) spaced 1 year apart. PARTICIPANTS: Sixty-seven eyes of 56 subjects with glaucomatous visual field loss from a natural history study of glaucoma were examined.
METHODS: Because both scoring systems are scaled so that they range from 0 to 20, the AGIS and CIGTS scores were compared by scatterplot, Pearson correlation, and the mean difference between scores. The difference between pairs of scores 1 year apart was used to compare the temporal variability of each scoring system. The proportion of subjects whose visual field "deteriorated" in 1 year by the amount specified for unconfirmed progression in each clinical trial was calculated. MAIN OUTCOME MEASURES: Mean difference in scores 1 year apart and the variance of these differences were measured.
RESULTS: The median scores for the first of the two fields was 5.2 (interquartile range [IQR] = 9.8) for CIGTS and 5.0 (IQR = 7.0) for AGIS. The CIGTS scores were slightly larger than AGIS scores by an average of 0.5 (P = 0.06). The mean CIGTS score of the baseline fields was 0.06 (standard deviation = 3.8) higher than the mean of the second fields and 0.12 (standard deviation = 2.8) higher for AGIS. Fifteen percent of eyes had CIGTS scores that deteriorated by three or more (the cutoff for unconfirmed progression) over 1 year, while 7.5% of eyes had AGIS scores that deteriorated by four or more (the AGIS cutoff for unconfirmed progression) over the same period. Twenty-one percent improved by CIGTS criteria, while 12% improved by AGIS criteria.
CONCLUSIONS: CIGTS scores are systematically slightly higher than AGIS scores. The CIGTS scoring system has higher temporal variability than the AGIS system. The CIGTS criterion for unconfirmed progression over a 1-year period is likely to lead to higher estimated rates of progression than the AGIS criteria. This is mostly because of the difference in the definition of progression between the two study criteria.

Entities:  

Mesh:

Year:  1999        PMID: 9951496     DOI: 10.1016/S0161-6420(99)90052-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  17 in total

1.  Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study.

Authors:  John L Keltner; Chris A Johnson; Richard A Levine; Juanjuan Fan; Kimberly E Cello; Michael A Kass; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2005-09

Review 2.  [Conventional techniques of visual field examination: part 4 Static perimetry: interpretation--perimetric indices--follow-up--perimetry in childhood].

Authors:  U Schiefer; J Pätzold; B Wabbels; F Dannheim
Journal:  Ophthalmologe       Date:  2006-03       Impact factor: 1.059

3.  Event-based analysis of visual field change can miss fast glaucoma progression detected by a combined structure and function index.

Authors:  Chunwei Zhang; Andrew J Tatham; Fábio B Daga; Alessandro A Jammal; Felipe A Medeiros
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-04-05       Impact factor: 3.117

Review 4.  Test-retest variability in structural parameters measured with glaucoma imaging devices.

Authors:  Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2012-11-09       Impact factor: 2.447

Review 5.  Functional assessment of glaucoma: Uncovering progression.

Authors:  Rongrong Hu; Lyne Racette; Kelly S Chen; Chris A Johnson
Journal:  Surv Ophthalmol       Date:  2020-04-26       Impact factor: 6.048

6.  Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe.

Authors:  C E Traverso; J G Walt; S P Kelly; A H Hommer; A M Bron; P Denis; J-P Nordmann; J-P Renard; A Bayer; F Grehn; N Pfeiffer; C Cedrone; S Gandolfi; N Orzalesi; C Nucci; L Rossetti; A Azuara-Blanco; A Bagnis; R Hitchings; J F Salmon; G Bricola; P M Buchholz; S V Kotak; L M Katz; L R Siegartel; J J Doyle
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

7.  Some dissociating factors in the analysis of structural and functional progressive damage in open-angle glaucoma.

Authors:  C J W Hudson; L S Kim; S A Hancock; I A Cunliffe; J M Wild
Journal:  Br J Ophthalmol       Date:  2006-10-18       Impact factor: 4.638

8.  Monitoring Glaucomatous Functional Loss Using an Artificial Intelligence-Enabled Dashboard.

Authors:  Siamak Yousefi; Tobias Elze; Louis R Pasquale; Osamah Saeedi; Mengyu Wang; Lucy Q Shen; Sarah R Wellik; Carlos G De Moraes; Jonathan S Myers; Michael V Boland
Journal:  Ophthalmology       Date:  2020-03-10       Impact factor: 12.079

9.  Evaluation of relationship between retinal nerve fiber layer thickness progression and visual field progression in patients with glaucoma.

Authors:  Kaori Tenkumo; Kazuyuki Hirooka; Tetsuya Baba; Eri Nitta; Shino Sato; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2013-06-25       Impact factor: 2.447

10.  Computerized expert system for evaluation of automated visual fields from the Ischemic Optic Neuropathy Decompression Trial: methods, baseline fields, and six-month longitudinal follow-up.

Authors:  Steven E Feldon
Journal:  Trans Am Ophthalmol Soc       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.